Elagolix
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild Autonomous Cortisol Excess
Conditions
Mild Autonomous Cortisol Excess
Trial Timeline
Jul 6, 2021 → Jun 24, 2022
NCT ID
NCT05038878About Elagolix
Elagolix is a approved stage product being developed by AbbVie for Mild Autonomous Cortisol Excess. The current trial status is terminated. This product is registered under clinical trial identifier NCT05038878. Target conditions include Mild Autonomous Cortisol Excess.
What happened to similar drugs?
7 of 16 similar drugs in Mild Autonomous Cortisol Excess were approved
Approved (7) Terminated (1) Active (8)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05038878 | Approved | Terminated |
| NCT02143713 | Phase 3 | Completed |
| NCT01931670 | Phase 3 | Completed |
| NCT01760954 | Phase 3 | Completed |
| NCT01620528 | Phase 3 | Completed |
Competing Products
20 competing products in Mild Autonomous Cortisol Excess